Q1 EPS Forecast for ArriVent BioPharma Boosted by Analyst

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – HC Wainwright increased their Q1 2025 earnings estimates for ArriVent BioPharma in a report issued on Wednesday, January 22nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.78) per share for the quarter, up from their previous estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS and FY2025 earnings at ($3.41) EPS.

ArriVent BioPharma Stock Up 0.2 %

ArriVent BioPharma stock opened at $27.30 on Friday. The firm’s fifty day moving average is $26.99 and its 200 day moving average is $26.09. ArriVent BioPharma has a 52-week low of $14.35 and a 52-week high of $36.37.

Institutional Investors Weigh In On ArriVent BioPharma

A number of hedge funds have recently bought and sold shares of AVBP. Rhumbline Advisers raised its stake in ArriVent BioPharma by 30.1% during the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock valued at $236,000 after purchasing an additional 2,942 shares in the last quarter. Novo Holdings A S raised its stake in ArriVent BioPharma by 39.3% during the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $27,825,000 after purchasing an additional 422,860 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of ArriVent BioPharma in the third quarter valued at $280,000. Charles Schwab Investment Management Inc. raised its stake in shares of ArriVent BioPharma by 153.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock valued at $4,756,000 after acquiring an additional 122,641 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of ArriVent BioPharma in the third quarter valued at $240,000. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.